Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis☆
References (36)
- et al.
The use and misuse of androgens
Metabolism
(1980) - et al.
High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs
Atherosclerosis
(1980) - et al.
Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoproteins in man
Atherosclerosis
(1980) - et al.
A tool for individualized management of fat controlled diets
J Am Diet Assoc
(1975) - et al.
Quantification of apolipoprotein A-I in human plasma high density lipoprotein
Metabolism
(1976) - et al.
Plasma high density lipoprotein concentration and development of ischemic heart disease
Lancet
(1975) - et al.
High density lipoproteins as a protective factor against coronary heart disease. The Framingham Study
AM J Med
(1977) - et al.
The distribution of plasma lipoproteins in middle-aged male runners
Metabolism
(1976) - et al.
Effects of oxandrolone on plasma triglycerides and post-heparin lipolytic activity in patients with types III, IV, and V familial hyperlipoproteinemia
Metabolism
(1971) - et al.
Triglyceride removal efficiency and lipoprotein lipases: effects of oxandrolone
Metabolism
(1973)
Relation of plasma high density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of man
Atherosclerosis
Reduction of plasma high density lipoprotein and cholesterol and increase of postheparin plasma hepatic lipase activity during progestin treatment
Clin Chim Acta
Stanozolol therapy in post-menopausal osteoporosis: Preliminary results
Clin Res
The national cost of acute care of hip fractures associated with osteroporosis
Clinical Orthopaedics & Related Research
Effect of oxandrolone treatment on the activity of lipoprotein lipase, hepatic lipase and phospholipase A1 of human postheparin plasma
New Engl J Med
Analyses of high density lipoprotein subclasses by precipitation procedure: Correlation with preparative and analytical ultracentrifugation
The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay
J Clin Invest
Cited by (107)
Sex and life expectancy
2012, Gender MedicineCitation Excerpt :Moreover, LDL concentrations have been shown to decrease abruptly, whereas HDL concentrations increase progressively, with increased HDL apolipoprotein A-I and A-II levels, in estrogen-supplemented menopausal women.49 In contrast, supplementation with androgens in postmenopausal women has been shown to have the opposite effect: LDL concentrations increase, whereas HDL and HDL apolipoprotein A-I and A-II concentrations decrease.50 Likewise, androgen supplementation in healthy men may initially decrease HDL-C and continue depression for the duration of testosterone supplementation.51
Acceleration of neutrophil precursors' maturation and immunostimulation of CD3 <sup>+</sup>, CD4 <sup>+</sup> lymphocytes by stanozolol in mice
2012, Journal of Steroid Biochemistry and Molecular BiologyCitation Excerpt :Because stanozolol is C-17 alpha-alkylated, it has the potential for liver toxicity, and as such we presume that considerable alterations in cholesterol profile reflect the adverse effects of stanozolol on liver enzymes such as hepatic triglyceride lipase (HTGL – an enzyme that regulates serum lipids and lipoproteins) and hepatic lipase resulting in a reduction of HDL-c. Disturbance in liver function has been already reported after treatment with 17α-alkylated compounds [26,27]. Also many studies have shown a decrease in HDL-c and lipoprotein (a) with distinct increase in HTGL activity [27–30]. This warrants further investigation on the effect of stanozolol on the liver enzymes.
Testosterone and the aging male: To treat or not to treat?
2010, MaturitasHepatic lipase and dyslipidemia: Interactions among genetic variants, obesity, gender, and diet
2003, Journal of Lipid ResearchCitation Excerpt :Colvin et al. demonstrated that orally administered micronized estradiol suppressed HL activity and increased HDL in a dose-dependent manner (64, 67). Synthetic progestational agents with androgenic activity (52, 68) and anabolic steroids both increase HL activity and lower HDL (64, 65, 67). Somekawa et al. recently showed that the HL promoter polymorphism (−514) had no effect on the lipid response to hormone replacement therapy in postmenopausal women.
Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers
2003, Journal of Steroid Biochemistry and Molecular BiologyHow the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health
2021, Reviews in Endocrine and Metabolic Disorders
- ☆
Supported in part by NIH grants HL 23474, HV-1-2157-L, CRC-RR-37, HL07028, HL 18645, HL 22381 & HL 22285.
- 1
During the tenure of these studies Dr. Taggart was supported by the Eastern Health and Social Services Board & the Northern Ireland Postgraduate Medical Council
- 3
Dr. Applebaum-Bowden a Research Associate of the Howard Hughes Medical Institute.
- 4
Dr. Albers is an Established Investigator of the American Heart Association.
- 2
Dr. Hazzard was an Investigator